Financials

  • Market Capitalization 9.71 B
  • Employee 730
  • Founded 1998
  • CEO N/A
  • Website www.corcept.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKJG33
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
115.17
Price to sales ratio
6.09

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
916
KRYS
Krystal Biotech, Inc. - Common Stock
339.43 USD-6.61%-7.91%+3.55%+81.39%10.01 B USD
925
NUVL
Nuvalent, Inc. - Class A Common Stock
123.96 USD+0.02%+0.18%+0.45%+30.55%9.79 B USD
955
KYMR
Kymera Therapeutics, Inc. - Common Stock
112.08 USD+1.52%-5.91%+30.51%+89.64%9.22 B USD
959
PRAX
Praxis Precision Medicines, Inc. - Common Stock
327.68 USD+4.17%+1.30%+23.69%+529.19%9.14 B USD

Frequently asked questions about Corcept Therapeutics Incorporated - Common Stock

What is the Corcept Therapeutics Incorporated - Common Stock stock price today?

The current price of Corcept Therapeutics Incorporated - Common Stock (CORT) is 90.47. Over the past 24 hours, the stock has changed by +5.32%. Follow the CORT chart for real-time price dynamics.

What is the stock ticker of Corcept Therapeutics Incorporated - Common Stock?

Corcept Therapeutics Incorporated - Common Stock trades under the ticker CORT. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Corcept Therapeutics Incorporated - Common Stock stock going up?

CORT has changed by -2.47% over the last week, +8.76% over the last month, and +23.31% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Corcept Therapeutics Incorporated - Common Stock net income for the last quarter?

Corcept Therapeutics Incorporated - Common Stock reported net income of -31.76 M for the last quarter. The previous quarter showed 24.29 M, which means net income changed by -230.77%.

How many employees does Corcept Therapeutics Incorporated - Common Stock have?

As of the latest available data, Corcept Therapeutics Incorporated - Common Stock has 730 employees. Workforce size can provide additional context about the company's scale and operations.

What is Corcept Therapeutics Incorporated - Common Stock EBITDA?

Corcept Therapeutics Incorporated - Common Stock EBITDA is -49 M, and its EBITDA margin is -29.72%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Corcept Therapeutics Incorporated - Common Stock stock?

You can buy Corcept Therapeutics Incorporated - Common Stock (CORT) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Corcept Therapeutics Incorporated - Common Stock stock?

Investing in Corcept Therapeutics Incorporated - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CORT chart and related analysis on metatrader.com as part of your research.

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

News